Real-World Cannabis Use Disorder During Pregnancy May Be Underestimated
By Lori Solomon HealthDay Reporter
WEDNESDAY, April 9, 2025 -- Commercial administrative claims data reveal slightly higher rates of cannabis use disorder (CUD) diagnoses during pregnancy than in previous research, according to a study published online Feb. 28 in the American Journal of Preventive Medicine.
Priscila Dib Goncalves, Ph.D., from the Columbia University Irving Medical Center in New York City, and colleagues examined the prevalence of CUD diagnosis during pregnancy among a large sample of commercially insured women from 2015 to 2020. The analysis included 893,430 pregnant women (aged 12 to 55 years), resulting in 1,058,448 pregnancies.
The researchers found that the cumulative prevalence of CUD diagnosis was 0.26 percent, which is slightly higher than previous research. Annual prevalence rates ranged from 0.22 percent in 2015 to 0.26 percent in 2020.
"Clinicians who regularly meet with pregnant women are well positioned to intervene in CUD but may lack the structural support to conduct relevant interventions. In addition, fear of legal repercussions related to disclosing substance use could serve as a barrier to medically appropriate interventions," the authors write. "Pregnant women’s willingness to disclose cannabis use to providers could be related to state punitive prenatal drug policies; addressing these policy barriers could impact the degree of underestimated CUD diagnoses."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
CRC as First of Multiple Primary Malignancies Tied to Better Outcomes Than CRC as Only Malignancy
THURSDAY, June 26, 2025 -- Compared with colorectal cancer (CRC) presenting as an isolated primary or second primary malignancy, CRC presenting as the first of multiple primary...
Two-Hour Observation Probably Safe for Most Children With Anaphylaxis
THURSDAY, June 26, 2025 -- For most children who present to an emergency department with an acute allergic reaction requiring epinephrine, a two-hour observation period is...
CT Perfusion and CT Angiography Not Useful as Standalone Tests for Establishing Death by Neurologic Criteria
THURDAY, June 26, 2025 -- Neither computed tomography (CT) perfusion nor CT angiography meet the prespecified validation threshold as an ancillary test for death by neurologic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.